Navigation Links
Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
Date:3/31/2008

r materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to: (i) the risk that our APTIMA HPV assay will perform poorly in this clinical trial, (ii) the risk that the APTIMA HPV assay will not be cleared for marketing in the timeframe we expect, if at all, (iii) the possibility that the market for the sale of our APTIMA HPV assay may not develop as expected, (iv) we may not be able to compete effectively with other companies already selling HPV diagnostic products or which launch such products in the future, (v) we depend on a small number of contract manufacturers and single source suppliers of raw materials, (vi) changes in third-party reimbursement policies regarding our products could adversely affect their sales, (vii) changes in government regulation affecting our products could harm our sales and increase our development costs, and (viii) litigation involving the assertion of third party patent rights could be expensive and divert management's attention, and/or result in damages or injunctive relief. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Michael Watts

Senior director, investor relations and

corporate communications

<
'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... RICHMOND, Va., April 18, 2011 BB&T Capital Markets ... LLC, d/b/a Dr. Comfort, the leading developer, manufacturer and ... products, in its sale to DJO Global, an international ... health and pain management based in Vista, Calif. Dr. ...
... GAITHERSBURG, Md., April 18, 2011 Sigma-Tau Pharmaceuticals, ... received approval from the U.S. Food and Drug ... in the oncology medicine ONCASPAR® (pegaspargase).  ONCASPAR is ... is a key component in the treatment of ...
Cached Medicine Technology:BB&T Advises Dr. Comfort on Its Sale to DJO Global in Transaction Valued at $254.6 Million 2Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 2Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 3Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 4
(Date:12/17/2014)... Alan Mozes HealthDay ... With the holiday party season fast approaching, a new study ... make DUI arrests have fewer drunk drivers on their roads. ... laws more vigilantly are better able to deter inebriated revelers ... "Hardly any new laws are being passed regarding drinking and ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... December 15, 2014 Health Dialog, ... announced today that it has received Patient Oriented ... (NCQA) for its Disease Management (DM) Programs for ... (COPD), coronary heart disease and diabetes. This marks ... for Health Dialog’s Disease Management (DM) Programs, reaffirming ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device regulatory consulting ... South America, Europe, the Middle East, Asia and Australia, ... 2015 Medical Device Industry Survey. Each year, Emergo conducts ... market trends as well as regulatory and operational concerns ... , Overall prospects for medical device ...
(Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Popular ,Out of the Closet, Thrift Store, Non-profit,AHF Pharmacy, ... Make a Difference, Grand Opening Event to Include ... This Saturday, February,2nd at 10:00 a.m., AIDS Healthcare ... Pharmacy, with a grand opening event to include,a ribbon-cutting ...
... enthused about Part D,s success, but critics say problems ... The three-year-old Medicare Part D drug program is seeing ... for the program fall, U.S. health officials announced Thursday. ... lower than originally projections, enrollment continues to rise and ...
... of the novel drug romiplostim (Nplate) show that it ... thrombocytopenic purpura (ITP), a hematologic disorder that can cause ... 3 trial results for the drug, which duplicates the ... General Hospital (MGH) investigator, in the February 2 issue ...
... International Associates, Inc.,administrator for the HealthShares(TM) Indexes, a ... Funds, today announced,that effective at the opening of ... BIM) will replace GYRUS GROUP PLC (GYG LN),in ... Companies that are included in The HealthShares(TM) ...
... in Karmanos Cancer Institute,s Annual Dinner, May 17, ... Karmanos,Cancer Institute will upgrade its nurse paging system, ... according to Nick Karmanos, vice,president of development for ... "As Lead Sponsor for our 26th Annual Dinner ...
... differences between nonprofit, for-profit banks should be explained , , ... tell pregnant patients considering umbilical cord blood banking about ... blood banks, new guidelines state. , The American College ... Opinion in the February issue of Obstetrics & ...
Cached Medicine News:Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 2Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 3Health News:Medicare's Drug Program Enrollment Up, Costs Down 2Health News:Medicare's Drug Program Enrollment Up, Costs Down 3Health News:Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder 2Health News:Ford Motor Company Fund Continues Longtime Support to Cancer Care 2Health News:Docs Should Tell All About Cord Blood Banks 2
... is a electronic medical records software for ... The Medical Office Records does more than ... designed to follow the flow of your ... previous encounters to establishing new examination records ...
... ChartMaker is a modular, Electronic Medical Record ... Windows to create a patient chart. ChartMaker ... E & M compliant patient notes, medical reports, ... template driven, ChartMaker is designed to be installed ...
... The eCHARMS suite comprises the ... 2000 product line. Currently, there ... signature & enterprise-wide disclosure reporting. ... new HIM management tool. These ...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
Medicine Products: